Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: Distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease

International Journal of Neuropsychopharmacology

Volumn 16, Issue 3, 2013, Pages 593-606

  Navailles, Sylvia ^a   Lagière, Mélanie ^a   Roumegous, Audrey ^a   Polito, Marina ^a   Boujema, Méric B ^a   Cador, Martine ^a   Dunlop, John ^b   Chesselet, Marie Françoise ^c   Millan, Mark J ^d   De Deurwaerdère, Philippe ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

6 OHDA lesion; Basal ganglia; orofacial movements; receptor intrinsic activity; serotonin2C receptors

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; N PYRIDIN 3 YL 1,2 DIHYDRO 3H BENZO[E]INDOLE 3 CARBOXAMIDE; S 32006; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; SEROTONIN 2 AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; INVERSE AGONISM; MOTOR DYSFUNCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN BINDING; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG INVERSE AGONISM; MALE; MOVEMENT DISORDERS; PARKINSON DISEASE, SECONDARY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 84874615490     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000417     Document Type: Article

References (53)

1. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, et al. (2005). Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55, 242-251. (Pubitemid 40256305)
2. Berendsen HH, Broekkamp CL, van Delft AM (1991). Depletion of brain serotonin differently affects behaviors induced by 5-HT1A, 5-HT1C, and 5-HT2 receptor activation in rats. Behavior and Neural Biology 55, 241-226.
3. Berg K, Navailles S, Sanchez T, Silva YM, et al. (2006). Differential effects of SB 243213 on 5-HT2C receptormediated responses. Journal of Pharmacology and Experimental Therapeutics 319, 260-268.
4. Beyeler A, Kadiri N, Navailles S, Boujema MB, et al. (2010). Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia. Neuroscience 169, 158-170.
5. Cath DC, Gijsman HJ, Schoemaker RC, van Griensven JMT, et al. (1999). The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome. Psychopharmacology (Berlin) 144, 137-143. (Pubitemid 29264429)
6. Chou-Green JM, Holscher TD, Dallman MF, Akana SF (2003). Compulsive behavior in the 5-HT2C receptor knockout mouse. Physiological Behavior 78, 641-649. (Pubitemid 36628092)
7. Cryan JF, Lucki I (2000). Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. Journal of Pharmacology and Experimental Therapeutics 295, 1120-1126.
8. De Deurwaerdère P, Chesselet MF (2000). Nigrostriatal lesions alter orofacial dyskinesia and c-fos expression induced by the serotonin agonist 1-(mcholophenyl) piperazine in adult rats. Journal of Neuroscience 20, 5170-5178. (Pubitemid 30421720)
9. De Deurwaerdère P, Mignon L, Chesselet MF (2011). Physiological and pathological aspects of 5-HT2C receptors in basal ganglia. In : di Giovanni G, di Matteo V, Esposito E (Eds.), The Pathophysiology of Central 5-HT2C Receptors. In: Neve K (Ed.), The Receptors Series. New York: Humana Press, Springer.
10. De Deurwaerdère P, Navailles S, Berg KA, Clarke WP, et al. (2004). Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. Journal of Neuroscience 24, 3235-3241. (Pubitemid 38451889)
11. De Deurwaerdère P, Stinus L, Spampinato U (1998). Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. Journal of Neuroscience 18, 6528-6538. (Pubitemid 28373254)
12. Dehning S, Mü ller N, Matz J, Bender A, et al. (2010). A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. Psychiatric Genetics 20, 35-38.
13. Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, et al. (2008). S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berlin) 199, 549-568.
14. Dekeyne A, Millan MJ (2009). Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats : A pharmacological characterization. Psychopharmacology (Berlin) 203, 329-341.
15. Dunlop J, Marquis KL, Lim HK, Leung L, et al. (2006). Pharmacological profile of the 5-HT2C receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Review 12, 167-177. (Pubitemid 46047786)
16. Dunlop J, Saab AL, Mazandarani H, Zhang J, et al. (2005). WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7, 1hi]indole], a novel 5-hydroxytryptamine2c receptor-selective agonist with anorectic activity. Journal of Pharmacology and Experimental Therapeutics 313, 862-869. (Pubitemid 40604189)
17. Eberle-Wang K, Lucki I, Chesselet MF (1996). A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 72, 117-128.
18. Gong L, Kostrzewa RM, Fuller RW, Perry KW (1992). Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. Journal of Pharmacology and Experimental Therapeutics 26, 1000-1007.
19. Graf M (2006). 5-HT2c receptor activation induces grooming behaviour in rats : possible correlations with obsessive-compulsive disorder. Neuropsychopharmacology Hungary 8, 23-28.
20. Gunes A, Dahl ML, Spina E, Scordo MG (2008). Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in mal schizophrenic patients. European Journal of Clinical Pharmacology 64, 477-482.
21. Hoyer D, Hannon JP, Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology Biochemistry Behavior 71, 533-554. (Pubitemid 34219205)
22. Kennett GA (1993). 5-HT1C receptors and their therapeutic relevance. Current Opinion in Investigational Drugs 2, 317-362.
23. Kennett GA, Ainsworth K, Trail B, Blackburn TP (1997). BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 36, 233-239. (Pubitemid 27149512)
24. Kennett GA, Wood MD, Bright F, Cilia J, et al. (1996). In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. British Journal of Pharmacology 117, 427-434.
25. Kostrzewa RM, Reader TA, Descarries L (1998). Serotonin neural adaptations to ontogenic loss of dopamine neurons in rat brain. Journal of Neurochemistry 70, 889-898. (Pubitemid 28113620)
26. de Leeuw AS, Westenberg HG (2008). Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with metachlorophrnylpiperazine and pre-treatment with ritanserin and placebo. Journal of Psychiatric Research 42, 894-901.
27. Lefkowitz RJ, Cotecchia S, Samama P, Costa T (1993). Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends in Pharmacological Sciences 14, 303-307. (Pubitemid 23242583)
28. McCreary AC, Cunningham KA (1999). Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology 20, 556-564. (Pubitemid 29189260)
29. Marquis KL, Sabb AL, Logue SF, Brennan JA, et al. (2007). WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10aoctahydro-7bH-cyclopenta-[b][1,4]diazepino [6,7,1hi]indole] : A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychoticlike activity. Journal of Pharmacology and Experimental Therapeutics 320, 486-496. (Pubitemid 46025760)
30. Martin JR, Bös M, Jenck F, Moreau JL, et al. (1998). 5-HT2C receptor agonists : pharmacological characteristics and therapeutic potential. Journal of Pharmacology and Experimental Therapeutics 286, 913-924. (Pubitemid 29003485)
31. Mayorga AJ, Cousins MS, Trevitt JT, Conlan A, et al. (1999). Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats. European Journal of Pharmacology 364, 7-11. (Pubitemid 29015781)
32. Mehta A, Eberle-Wang K, Chesselet MF (2001). Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons. Pharmacology Biochemistry Behavior 68, 347-353. (Pubitemid 32231197)
33. Millan MJ (2005). Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states : focus on novel therapeutic strategies. Therapie 60, 114-460.
34. Millan MJ, Marin P, Kamal M, Jockers R, et al. (2010). The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors. International Journal of Neuropsychopharmacology 15, 1-16.
35. Navailles S, Bioulac B, Gross C, De Deurwaerdère P (2010). Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiology of Disease 38, 136-143.
36. Navailles S, De Deurwaerdère P (2011). The constitutive activity of 5-HT2C receptors as an additional modality of interaction of the serotonergic system. In : di Giovanni G, di Matteo V, Esposito E (Eds.), The Pathophysiology of Central 5-HT2C Receptors. In: Neve K (Ed.), The Receptors Series. New York: Humana Press, Springer.
37. Navailles S, Moison D, Ryczko D, Spampinato U (2006). Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors. Journal of Neurochemistry 99, 1311-1319. (Pubitemid 44655294)
38. Nozulak J, Kalkman HO, Floersheim P, Hoyer D, et al. (1995). (+)-cis-4,5,7a,8,9,10,11,11a-octohydro-7H-10-methylindolo[1,7-bc][2,6] -naphthyridine : A 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity. Journal of Medicinal Chemistry 38, 28-33.
39. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. New York: Academic.
40. Pazos A, Cortés R, Palacios JM (1985). Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Research 346, 231-249. (Pubitemid 16241112)
41. Pellegrino LJ, Cushman AJ (1967). A Stereotaxic Atlas of the Rat Brain. New York: Academic.
42. Plech A, Brus R, Kalbfleisch JH, Kostrzewa RM (1995). Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology (Berlin) 119, 466-473.
43. Pompeiano M, Palacios JM, Mengod G (1994). Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Research Molecular Brain Research 23, 163-178.
44. Reynolds GP, Templeman LA, Zhang ZJ (2005). The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 1021-1028. (Pubitemid 41080129)
45. Robinson ES, Dalley JW, Theobald DE, Glennon JC, et al. (2008). Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology 33, 2398-2406.
46. Rocha B, Di Scala G, Rigo M, Hoyer D, et al. (1993). Effect of 5,7-dihydroxytryptamine lesion on mianserininduced conditioned place aversion and on 5-hydroxytryptamine1C receptors in the rat brain. Neuroscience 56, 687-693. (Pubitemid 23290580)
47. Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, et al. (2007). Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berlin) 192, 159-170. (Pubitemid 46669211)
48. Simansky KJ, Dave KD, Inemer BR, Nicklous DM, et al. (2004). A 5-HT2C agonist elicits hyperactivity and oral dyskinesia with hypophagia in rabbits. Physiological Behavior 82, 97-107. (Pubitemid 38968515)
49. Stewart BR, Jenner P, Marsden CD (1989). Induction of purposeless chewing behaviour in rats by 5-HT agonists drugs. European Journal of Pharmacology 162, 101-107. (Pubitemid 19074881)
50. Tecott LH, Sun LM, Akana SF, Strack AM, et al. (1995). Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374, 542-546.
51. Wolf WA, Bieganski GJ, Guillen V, Mignon L (2005). Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced 'early onset' vacuous chewing in rats : implications for antipsychotic drug therapy. Psychopharmacology (Berlin) 182, 84-94. (Pubitemid 41400865)
52. Wood MD, Reavill C, Trail B, Wilson A, et al. (2001). SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41, 186-199. (Pubitemid 32728090)
53. Zhang X, Andren PE, Svenningsson P (2007). Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiology and Behavior 92, 29-33. (Pubitemid 47374252)